In the current study, 2.5% of cases were co-infected with HIV+TB+. This is similar to a report from Georgia with 1.7 to 2.2% co-infection rate (
12) and another study from Saudi Arabia indicating that 1.35% of individuals become co-infected per year (
13). In contrast, a research from Iran, reported that nearly 24% of Iranian patients with HIV/AIDS were infected with MTB (
14). Another study from Nigeria showed that 28.2% of TB patients under study were co-infected with HIV (
15). A report performed on different patient groups in St. Petersburg, Russia, confirmed the presence of TB in 77% of HIV-infected cases, in all groups belonging to the Beijing family (
16). The discrepancy of our results with some of the previous literature may be because a portion of HIV infected cases, due to cultural and social beliefs may not have referred to related medical centers for treatment (
17).
The results of the current study established the significant difference of survival rate between HIV+TB+ co-infected patients and TB infected patients (P value < 0.001). The assessment of risk factors by Cox regression analysis on 828 patients showed that co-infection with HIV significantly affects the survival rate of TB patients so that the rate of death was 20.7 (8.1-53) times more than patients infected with TB alone. This finding was as expected. In HIV+TB+ patients, married cases were more prone to death than single individuals (P value < 0.01) (
Table 2). The latter results provide some interesting insight into the subject of the current research. The reason may due to greater sexual activity of married patients compared to singles, which increases the likelihood of sexually transmitted diseases (STDs).
Moreover, progress of TB in HIV patients is influenced by both genetic and environmental components that could be an additional explanation for the obtained results. However, the suggested reasons need further exploration in future studies. Also, multivariate analysis confirmed that the married patients with tuberculosis were 2.7 times more at risk for TB death than single cases (P value < 0.02) (not shown). Nevertheless, a research in Thailand showed that married patients were at lower risk of TB death (
18). The discrepancy between our findings and the literature remains to be fully understood. Other factors such as sex, residential area, age, job, receiving or lack of HAART, AIDS stage and sputum smear test did not have any significant effect on the survival of HIV+TB+ patients (
Table 2). In contrast, a research from Iran showed that sex and marital status were significant factors as well (
14).
Furthermore, the current study found significant differences in the survival rate of different categories of (after initiation of symptoms, diagnosis of infection and initiation of treatment) HIV+TB+ co-infected patients compared to TB infected patients (P value < 0.001) so that the survival rate of HIV+TB+ co-infected patients was shorter than patients infected with TB alone in all of the above mentioned conditions. Thus far in this research, it seems that initiation of symptoms, diagnosis of infection and initiation of treatment are well established predictive factors of survival rate in HIV+TB+ co-infected patients. This may be explained by the much more severe immunodeficiency status of HIV+TB+ co-infected patients.
Under our conditions the survival rate of
tuberculosis/HIV co-infected patients with positive HAART at one, two, three and five years were 91%, 83%, 66%, 45% and in those with negative HAART, survival rates were 56%, 44%, 32% and 12%, respectively. In contrast, the survival rate of tuberculosis infected patients who underwent treatment at one, two, three and five years were 91%, 82%, 71% and 62%, respectively. A study from Thailand performed on HIV-infected patients with TB showed that the chance of survival after diagnosis of TB infection at one, two, and three years were respectively, 96.1%, 94.0%, and 87.7% for positive HAART patients and 44.4%, 19.2% and 9.3% for those who did not receive HAART (
6). Moreover, survival advantage of HAART in the HIV-infected population is probably due to eradication of drug resistance TB in these patients (
19).
A report from Rio de Janeiro indicated that the rates of cure, treatment abandonment, and mortality of TB were 72%, 19% and 6%, respectively (
20). Out of 21 patients, 12 (57.1%) patients started HAART while nine (42.9%) patients did not use medication for the treatment of AIDS. Our research showed that the median of survival time in positive HAART patients and in those who did not receive HAART were 48 and 25 months, respectively. Log-rank analysis (log-rank = 5.2) confirmed significant differences between the two groups (P value = 0.03), which prioritize the critical role of monitoring response to treatment.
The limitation of the current study was the low number of co-infected patients. However, the strength of this study was the diagnosis criteria; diagnosis of M.tuberculosis infection based on a positive TB sputum smear test and the confirmation of HIV positives by the western blotting method. In conclusion, this paper investigates mortality in HIV-associated TB and the predictors of survival and death in patients from a western province of Iran. The current results showed that in HIV-TB+ patients, age, sex and site of TB were significant factors in mortality of patients. This research indicated that the rate of death was 20.7 times greater in HIV/TB co-infected patients than cases infected with TB alone. This appears to be consistent with the literature.
Overall, the current study shows the necessity for rapid treatment and broader surveillance of co-infection with HIV and tuberculosis especially in infected married individuals, which were more prone to death than single cases. This will include development of further policies, in order to control and reduce the risk of TB/HIV infections. Control of infections by progress in diagnostic and preventive measures such as provision of isoniazid preventive therapy, HIV testing of TB patients, combination of TB and HIV services, control and reduction of the risk of recurrent TB in latent infections will be needed to raise hope for broad surveillance of co-infected patients.